Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin dose-comparison trial in adults with generalised anxiety disorder
ISRCTN14487299Phase 2Terminated
- Sponsor
- Incannex Healthcare
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in generalized anxiety disorder (GAD) (2 arms), sponsored by Incannex Healthcare. Primary endpoint: Change from baseline in Hamilton Anxiety Rating Scale total score at week 8. Started Apr 2026; status: terminated.
02
Drugs
psilocybin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on ISRCTN14487299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14487299.